Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNL921 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Experimental Arm | EXPERIMENTAL | - |
| Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| DNL921 | DRUG | Single or multiple doses |
| Placebo | DRUG | Single or multiple doses matched to experimental treatment |
Key Inclusion Criteria (Healthy Participants): * Are male or female of non-childbearing potential and are aged 18 through 60 years at the time of screening * Have a BMI of 18 through 32 kg/m2 and a body weight of at least 50 kg * For female participants: Are of non-childbearing potential * For male...
Top 20 of 24 competitors
DNL921 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied in healthy participants and in people with Alzheimer's Disease to evaluate its safety, pharmacokinetics, and pharmacodynamics.
DNL921 targets Abeta, a protein that forms amyloid plaques in the brain, which are a hallmark of Alzheimer's Disease. By targeting this protein, the drug aims to address a key pathological feature of the disease. The drug is a small molecule designed to interact with this target.
DNL921 is being developed by Denali Therapeutics Inc., a biopharmaceutical company traded on the Nasdaq under the ticker symbol DNLI. The company is conducting a Phase 1 clinical trial of DNL921 in the United Kingdom, which is currently recruiting participants.
DNL921 is in Phase 1 clinical development. The drug is investigational and has not been approved by the FDA or any other regulatory agency. It is being studied in a single Phase 1 trial that is currently recruiting participants, with an enrollment target of 178 individuals.
DNL921 is being studied in a Phase 1 clinical trial with the identifier NCT07758595. The trial is titled 'A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease.' It is a randomized, double-blind, placebo-controlled study conducted in the United Kingdom.
DNL921 is a unique investigational drug candidate developed by Denali Therapeutics Inc. It is not known to be the same as any other approved or investigational medication. The drug is being evaluated specifically for its potential role in treating Alzheimer's Disease by targeting the Abeta protein.